President Donald Trump announced a comprehensive effort to lower drug costs in the United States. He revealed the creation of a “TrumpRx” direct-to-consumer website where Americans can purchase medicine at discounted prices. Trump also announced a significant deal with Pfizer to reduce the prices of many of its products.
“The United States is done subsidizing the health care of the rest of the world,” Trump said at a news conference. “By taking this bold step, we’re ending the era of global price gouging at the expense of American families.”
Pfizer is the first drugmaker to voluntarily agree to all the demands Trump laid out in a recent letter to pharmaceutical company CEOs. The president hinted that others might soon follow.
Pfizer will sell drugs to Medicaid at the lowest price available in peer countries. Additionally, primary care medications and some specialty brand-name drugs will be available at a 50% savings, on average, through TrumpRx. The TrumpRx site, which will not go live until early 2026, will not directly sell or distribute medications.
Instead, consumers will be able to search for their medicines and will be redirected to manufacturers’ direct-to-consumer channels. Trump acknowledged that these actions might lead to higher drug prices in other countries while reducing costs in the United States, a trade-off he described as “fair.” Industry experts, however, have questioned whether his efforts will truly lower the prices Americans pay for drugs, which often depend on insurance coverage and the complex drug industry supply chain. Trump has long been vocal about the fact that Americans pay significantly more for medications than people in peer countries, particularly in Europe, where governments often determine drug costs.
TrumpRx for cheaper medicine prices
Prices are nearly three times as high in the US as they are in comparable countries, according to a Health and Human Services Department report released last year. During his first term, Trump unsuccessfully attempted to institute “Most Favored Nation” pricing, which he revived in May by directing drugmakers to start offering US patients these globally competitive prices or face consequences.
The administration clarified that “Most Favored Nation” pricing would be based on the net price of medications, considering discounts and rebates, compared to the lowest price in other wealthy countries. This price would become the benchmark for the US. Pfizer will start offering Medicaid “Most Favored Nation” prices in early 2026.
Additional manufacturers are in negotiations with the administration, and more companies are expected to join the initiative. Several drug industry experts, however, are skeptical about the effectiveness of the TrumpRx initiative. Chris Meekins, managing director of health policy research at Raymond James, noted that few consumers are likely to pay out-of-pocket unless there are changes in insurance policies.
Stacie Dusetzina, a professor of health policy at Vanderbilt University Medical Center, questioned the practicality of some of the prices offered through TrumpRx. The drug industry has warned that implementing “Most Favored Nation” pricing could have serious consequences. Alex Schriver, senior vice president at PhRMA, stated, “Importing foreign price controls would undermine American leadership, hurting patients and workers.”
As part of the deal announced Tuesday, Pfizer said it will invest an additional $70 billion in research and manufacturing projects over the coming years and will receive a three-year grace period on certain tariffs the administration plans to impose.
Overall, Trump’s announcement marks another step in his ongoing efforts to get drugmakers to reduce their prices, a central goal since his first presidential campaign.
